This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

This study has been completed.
McLaughlin-Rotman Center for Global Health, University of Toronto
Information provided by (Responsible Party):
Mahidol University Identifier:
First received: September 6, 2005
Last updated: April 10, 2015
Last verified: April 2015
The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.

Condition Intervention Phase
Falciparum Malaria Drug: Rosiglitazone Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection

Resource links provided by NLM:

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • Time to clearance (in hours) of parasitemia from blood is recorded [ Time Frame: 5 days ]

Secondary Outcome Measures:
  • Time to resolution of fever (in hours) [ Time Frame: 5 days ]
  • AST/ALT levels (U/L) [ Time Frame: 2 days ]
  • Capillary blood glucose (mmol/L) [ Time Frame: 2 days ]
  • Need for ICU admission [ Time Frame: 5 days ]
  • Tolerability of study drug/placebo as assessed by patient log [ Time Frame: 5 days ]

Enrollment: 140
Study Start Date: December 2004
Study Completion Date: January 2006
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 2 Drug: Placebo
Experimental: 1 Drug: Rosiglitazone

Detailed Description:

Study Rationale: Evidence suggests that if PPAR-RXR agonists (such as rosiglitazone) are used as adjunctive therapy in P. falciparum malaria infections they may increase phagocytic clearance of P. falciparum malaria, modulate deleterious inflammatory responses and decrease sequestration of malaria parasites in vital organs. They may therefore represent a novel immunomodulatory treatment approach for P. falciparum malaria.

Study Objectives: 1) To examine the in vivo effect of rosiglitazone on the rapidity of clearance of P. falciparum parasitemia and fever in patients with non-severe P. falciparum infections 2) To assess the safety and tolerability of adjunctive rosiglitazone treatment in non-severe cases of P. falciparum infection.

Primary Outcomes: Time to clearance of P. falciparum parasitemia

Study Design: Randomized double blind placebo-controlled trial.

Intervention: Standard antimalarial treatment (atovaquone/proguanil) to all patients combined with adjuvant rosiglitazone treatment (8mg per day) or placebo.

Setting: Hospital for Tropical Diseases at Mahidol University, Thailand.

Participants: 140 patients with non-severe P. falciparum infection.

Follow-up: 28 days


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Microscopically confirmed P.falciparum infection
  • Age >18 years
  • Able to tolerate oral therapy
  • Able to give informed consent

Exclusion Criteria:

  • Fulfillment of WHO criteria for severe/cerebral malaria
  • Prior treatment with any thiazolidinedione
  • Allergy to rosiglitazone
  • History of diabetes mellitus
  • History of severe/decompensated liver disease
  • ALT level >2.5 times normal
  • Current treatment for congestive heart failure
  • Pregnancy or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00149383

Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand, 10400
Sponsors and Collaborators
Mahidol University
McLaughlin-Rotman Center for Global Health, University of Toronto
Principal Investigator: Kevin C Kain, MD, FRCPC Faculty of Medicine, University of Toronto; McLaughlin-Rotman Center for Global Health, Toronto
  More Information

Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mahidol University Identifier: NCT00149383     History of Changes
Other Study ID Numbers: 033-2004
Study First Received: September 6, 2005
Last Updated: April 10, 2015

Keywords provided by Mahidol University:
randomized controlled trial
Plasmodium falciparum

Additional relevant MeSH terms:
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017